Analysis Tools
growth/size/body
|
• mild
|
|
• 15-20 fold increase in spleen weight
• expanded erythroid and myeloid cells in spleen
|
endocrine/exocrine glands
|
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• mice with lymphomas do not develop myeloproliferative disease
|
liver/biliary system
| N |
• ethanol feeding does not induce liver steatosis
|
|
• slightly elevated liver triglycerides with ethanol feeding
|
|
• liver weight/body weight ratio does not increase with ethanol feeding as happens with controls
|
|
• hepatocellular proliferation after partial hepatectomy normal for first 36 hours
• proliferation is significantly reduced at 48 hours
|
cellular
|
• mitosis impaired between metaphase and anaphase
|
|
• lower frequency of mitosis in the liver 48 hours after hepatectomy
• frequency of mitosis in the liver remains more or less constant from 48 to 72 hours after hepatectomy
|
neoplasm
|
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• mice with lymphomas do not develop myeloproliferative disease
|
|
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
|
|
• skin tumors induced by treatment with DMBA and TPA appear to be papillomas
|
|
• mice treated with the mutagen DMBA and tumor promoter TPA develop skin tumors around 8 weeks rather than 12.5 weeks as in controls
|
homeostasis/metabolism
|
• serum alanine aminotransferase is not increased by ethanol feeding whereas levels increase 2 fold in controls
|
|
• slightly elevated liver triglycerides with ethanol feeding
|
|
• TNF alpha levels remain constant with ethanol feeding whereas they increase 20 fold in controls
|
|
• liver weight/body weight ratio does not increase with ethanol feeding as happens with controls
• serum alanine aminotransferase is not increased by ethanol feeding whereas levels increase 2 fold in controls
• TNF alpha levels remain constant with ethanol feeding whereas they increase 20 fold in controls
• no effect of ethanol diet on LPS sensitivity
|
|
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
|
|
• infarcts are much smaller in total area after temporary middle cerebral artery occlusion
• neurological deficits are mild
• less edema than in controls
|
|
• reduced rate of wound healing
• less collagen deposition
• fewer alpha smooth muscle cell positive myofibroblasts
|
hematopoietic system
|
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• mice with lymphomas do not develop myeloproliferative disease
|
|
• 15-20 fold increase in spleen weight
• expanded erythroid and myeloid cells in spleen
|
|
• ineffective erythropoiesis in bone marrow and spleen
|
|
• two fold increase in hematopoietic stem cells in the S/G2-M phase of the cell cycle
• no buildup of stem cells in the bone marrow
• level of circulating hematopoietic stem cells is dramatically increased
|
|
• dysplastic neutrophils in bone marrow and spleen
|
|
• mildly elevated
|
|
• elevated numbers of activated microglial cells an macrophage but fewer than in controls
|
immune system
| N |
• no effect of ethanol diet on LPS sensitivity
|
|
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• mice with lymphomas do not develop myeloproliferative disease
|
|
• 15-20 fold increase in spleen weight
• expanded erythroid and myeloid cells in spleen
|
|
• dysplastic neutrophils in bone marrow and spleen
|
|
• mildly elevated
|
|
• elevated numbers of activated microglial cells an macrophage but fewer than in controls
|
|
• TNF alpha levels remain constant with ethanol feeding whereas they increase 20 fold in controls
|
|
• lower inflammatory response to four daily subcutaneous bleomycin injections
• lower inflammatory response to a single subcutaneous TGF beta injection
|
respiratory system
| N |
• bleomycin induced lung pathologies are attenuated
|
|
• number and size of subpleural and interstitial fibrotic foci is reduced
• diminished collagen accumulation
|
|
• reduced
|
vision/eye
|
• smaller radius of curvature at 40 days of age than in controls
|
|
• deeper anterior chamber of the eye at 56 days of age
|
|
• longer eyes (axial eye length) than controls at 42 days of age
|
|
• reduced refraction relative to controls
|
nervous system
|
• elevated numbers of activated microglial cells an macrophage but fewer than in controls
|
|
• infarcts are much smaller in total area after temporary middle cerebral artery occlusion
• neurological deficits are mild
• less edema than in controls
|
integument
|
• bleomycin induced dermal thickening more modest than in controls
• less sclerotic than controls
• less collagen accumulation
• reduced accumulation of alpha-smooth musclew actin myofibroblasts
|
|
• skin tumors induced by treatment with DMBA and TPA appear to be papillomas
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| myelodysplastic syndrome | DOID:0050908 |
OMIM:614286 |
J:123870 | |
